Navigation Links
OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
Date:12/1/2009

ent," said Dr. Thambar. "This innovative technology potentially represents the next generation of coronary stents."

The Combo Stent is designed to combine the pro-healing technology used in OrbusNeich's Genous(TM) Bio-engineered R stent(TM) for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. The low dose sirolimus elution is accomplished through the use of the SynBiosys(TM) biodegradable polymer matrix from SurModics, Inc. ( SRDX).

"The pre-clinical work has shown the effectiveness of combining the endothelial progenitor cell capture technology to promote endothelialization coupled with the low dose, abluminal sirolimus elution to regulate hyperplasia," said Ian T. Meredith, M.B.B.S., Ph.D., Professor of Cardiology, Director of MonashHeart and Executive Director of the Monash Cardiovascular Research Centre, Melbourne, Australia, one of the trial's principal investigators. The other principal investigators are Stephan Windecker, M.D., director of invasive cardiology at the University Hospital Bern in Switzerland, and Alexandre Abizaid, M.D., Ph.D., director of the catheterization laboratory at the Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. "The Combo Stent could be the best of both world's approach for patients at the highest risk of restenosis," Meredith added.

"The Combo Stent has demonstrated significantly lower neointimal hyperplasia, improved endothelial coverage relative to commercially available drug-eluting stents and lower presence of inflammation and foreign body reaction in multiple pre-clinical studies," said Renu Virmani, M.D., president and medical director of CVPath Institute, Inc. "Furthermore, I have long believed that the next generation of stents can benefit from biodegradable polymers. The data I've seen on the SynBiosys biodegradable polymer suggest it is very biocompatible with low inflammatory scores that could also resul
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
2. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
3. OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation Catheter
4. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
5. OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
6. OrbusNeich Receives CE Mark Approval for Scoreflex(TM) Coronary Dilatation Catheter
7. OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently received ... in metastatic breast cancer reduces both the growth of ... scientists have found in models of the disease that ... 80 percent and can keep the tumor from metastasizing ... grant comes from the National Cancer Institute of the ...
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... Glan Clywd Hospital will soon offer local cancer patients ... radiotherapy technology on two new treatment machines from Varian ... the Clinac(R) linear accelerators with RapidArc are installed, the ... to offer this new, faster form of radiotherapy that ...
... (NYSE: DHR ) announced today that ... quarterly dividend of $0.03 per share payable on ... June 26, 2009.Danaher Corporation is a leading manufacturer ... Tools and Components ( www.danaher.com ). ...
... Outpatient, Inpatient SettingsBOSTON, May 7 MedAptus(R), market ... the distinguished Lenox Hill Interventional Cardiac & Vascular ... to implement Professional Intelligent Charge Capture. Nearly ... of the most highly respected cardiovascular care programs ...
... Ohio, May 7 STERIS Corporation (NYSE: STE ... a 38% increase in its quarterly dividend to $0.11 per ... to shareholders of record at the close of business on ... of STERIS Corporation is to provide a healthier today and ...
... EPS Guidance , WARSAW, Ind., May 7 First Quarter 2009 Highlights: ... Revenue of $101.4 million, comparable year-over-year and up 6.8% on a constant currency ... 24.2%, up 70 basis points year-over-year and up 80 basis points over the ... Operating income of $11.2 million, up 17.2% year-over-year and up 18.2% over the ...
... a.m. EDT at www.isispharm.com CARLSBAD, Calif., May 7 ... announced its financial results for the quarter ended March 31, ... gain that Isis recognized from selling its Ibis Biosciences subsidiary ... of 2009 with pro forma net income of $173.0 million. ...
Cached Medicine News:Health News:Cancer Patients in North Wales to Gain Access to Varian's RapidArc Radiotherapy Treatments 2Health News:MedAptus' Charge Capture Technology Deployed at Leading Manhattan Cardiovascular Practice 2Health News:MedAptus' Charge Capture Technology Deployed at Leading Manhattan Cardiovascular Practice 3Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 3Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 2Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 3Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 4Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 5Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 6Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 7Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 8Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 2Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 3Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 4Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 5Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 6Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 7Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 8Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 9Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 10Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 11Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 12Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 13Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 14Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 15Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 16Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 17Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 18
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Four 62 mirrors ... the angle with little ... flange is convenient for ... fissures. Anterior holding ring ...
Small size gonio lens with one 62 mirror. Compact knurled ring simplifies 360 viewing of the anterior chamber angle....
Mcintyre straight lachrymal cannula, closed end, two side ports at 0.3 mm, straight shaft....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Medicine Products: